Pharmaceuticals

Repairing the Spine: Q&A with NervGen CEO Mike Kelly

bexib
By bexib 0 Min Read

Kelly explains how the company is taking a different approach to spinal cord injuries.

You Might Also Like

FDA approves AstraZeneca’s Imfinzi in combination with chemotherapy for resectable early-stage non-small cell lung cancer

Pharma Pulse 8/20/24: CRAACO Evolution, Pain Relief for HIV-Infected People and More

Researchers develop genetic mole-removal therapy for rare skin disease

Beyond Fertility: The Social Cost of Maternal Mortality

Discovering New Molecules and Indications Through Synthesis: Q&A with Dr. Joe Varshney

Share This Article
Previous Article Kamala’s national security adviser points to continuity of Biden’s Russia policy
Next Article Leading with Love – Angie Turner, Executive Housekeeper
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Chart: AI outlook, employee vs. Q1 2025
Retail & E-commerce
10 Made in America Valentine’s Gift Ideal from Etsy
Manufacturing
SUMSUB starts Australian DVS verification of safe ID check
Fintech
Indian cash -free payments secure the $ 53 million US funded by PUBG Publisher Krafton.
Fintech